Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
35.47 USD | -2.04% |
|
-0.25% | -10.24% |
06-18 | Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target | MT |
06-11 | Celldex Therapeutics Insider Sold Shares Worth $1,586,844, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.24% | 2.39B | |
+26.51% | 52.73B | |
+37.49% | 39B | |
-9.39% | 38.52B | |
+28.49% | 30.38B | |
-12.26% | 26.39B | |
+11.75% | 26.08B | |
+45.05% | 14.15B | |
+32.85% | 12.6B | |
-5.52% | 11.51B |
- Stock Market
- Equities
- CLDX Stock
- News Celldex Therapeutics, Inc.
- Insider Sell: Celldex Therapeutics